James Edgemond Sells 7,785 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond sold 7,785 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the transaction, the chief financial officer now owns 2,615 shares in the company, valued at approximately $947,597.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $353.37 on Thursday. The firm has a market capitalization of $15.67 billion, a price-to-earnings ratio of 16.71, a PEG ratio of 1.31 and a beta of 0.55. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The business’s 50-day moving average price is $332.63 and its 200-day moving average price is $281.44. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $366.08.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The business had revenue of $714.90 million for the quarter, compared to analyst estimates of $691.87 million. During the same quarter in the prior year, the business earned $5.24 earnings per share. The firm’s quarterly revenue was up 19.8% on a year-over-year basis. Equities research analysts forecast that United Therapeutics Co. will post 24.86 EPS for the current year.

Institutional Trading of United Therapeutics

Several institutional investors have recently modified their holdings of the business. SG Americas Securities LLC increased its position in United Therapeutics by 176.2% during the 1st quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock valued at $3,288,000 after purchasing an additional 9,133 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of United Therapeutics by 19.0% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after buying an additional 4,100 shares during the period. International Assets Investment Management LLC raised its stake in United Therapeutics by 13,769.2% during the fourth quarter. International Assets Investment Management LLC now owns 9,015 shares of the biotechnology company’s stock worth $1,982,000 after buying an additional 8,950 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in United Therapeutics by 90.3% in the fourth quarter. BNP Paribas Financial Markets now owns 55,481 shares of the biotechnology company’s stock valued at $12,200,000 after buying an additional 26,325 shares during the period. Finally, Comerica Bank boosted its position in United Therapeutics by 5.9% during the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock valued at $38,113,000 after acquiring an additional 9,244 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of analyst reports. TD Cowen increased their price objective on shares of United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Morgan Stanley cut shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. Bank of America cut their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research note on Thursday, August 1st. LADENBURG THALM/SH SH lowered United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, UBS Group boosted their price target on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $350.36.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.